A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for theTreatment of Unresectable and Metastatic Conventional Chondrosarcoma
Study of Belinostat and Guadecitabine for Treatment of Chondrosarcoma
Sponsor: National Cancer Institute
Enrolling: Male and Female Patients
IRB Number: AAAT2009
U.S. Govt. ID: NCT04340843
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the good and bad effects of the drugs called belinostat and SGI-110 (guadecitabine). These drugs could shrink your cancer, but they could also cause side effects. The study doctors hope to learn if the study drugs will shrink the cancer more often than observed with other standard treatment options. We dont know if belinostat or SGI-110 (guadecitabine) work to treat chondrosarcoma in people, but they have been used in other clinical trials and are noted to be well-tolerated in patients with other types of cancer.
Investigator
Shaheer Khan, DO
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with chondrosarcoma that cannot be removed by surgery? Yes No
Are you able to come to the clinic for 5 consecutive days each month to get treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE